Slides
Page 1
2026 Investor Day September 24, 2026 Scan QR code for microsite & presentation
Page 2
Welcome Todd Spencer | Corporate Vice President, Investor Relations
Page 3
2026 INVESTOR DAY3 Safe Harbor Statement Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements about: our future (annual or other) financial performance and drivers thereof (including, without limitation, revenue and revenue growth rates, operating income and margin, earnings per share, capital expenditures, operating and free cash flow, net interest expense, effective tax rate and tax benefits, corporate expenses, and leverage ratios) whether reported, constant currency, organic, and/or factoring acquisitions and/or divestitures, with respect to Charles River as a whole and/or any of our reporting or operating segments or business units, including the assumptions that form the basis for such guidance and targets; the Company’s expectations concerning projected other future financial and operating performance, including with respect to booking activity and related financial metrics; the Company’s commitment to, and ability to create long-term value for shareholders and to successfully execute on the strategies described herein; the impact of operations and cost structure alignment and efficiency efforts, including, without limitation, our Pathway to Purpose strategic focus, including the ability to drive profitable revenue growth and operating margin expansion, the ability to implement intended modernization efforts, strengthen our scientific portfolio and apply and benefit from our designed customized, client-centric approach; client demand, including trends and the future demand for the Company’s products and services; the impact of foreign exchange; our expectations with respect to cost savings (annualized or other); changes and uncertainties in the global economy and financial markets; our expectations with respect to the impact of external interest rate fluctuations (including the impact of potential changes in Federal Reserve interest rates); client demand, including the impact of demand trends and KPIs, and our ability to increase client interest and the future demand for drug discovery and development products and services; our intentions to expand our businesses, including our investments in our portfolio; our expectations with respect to our cancellation rate and the impact of such cancellations; the timing of business developments, including timing of scientific enhancements to support such developments and our expectations with respect to the use of New Approach Methodologies (“NAMs”), including adoption timing and the financial impact of our continued investments in NAMs; the impact of significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition, including tariffs and proposed tariffs and our expectations with respect to offsetting associated costs; our expectations regarding stock repurchases and debt repayment; the development and performance of our services and products, including expectations with respect to reducing timelines for our customers; expectations with respect to pricing of our products and services; market and industry conditions, including industry consolidation and the Company’s share of any market it participates in; our expectations regarding the continued outsourcing of services and identification of spending and scheduling trends by our clients and funding available to them; our expectations regarding the availability of NHPs, including the number of NHPs utilized in our studies and fluctuations in the number of NHPs sourced from origin countries; our expectations with respect to the adoption of animal alternatives; our expectations with respect to sourcing of NHPs, including our ability to effectively manage potential constraints on NHP supply, including expectations with respect to the timing of shipments of NHPs; our expectations with respect to oversight of animal welfare, biosecurity, and regulatory compliance; the impact of the Company’s efforts to gain additional market share; the potential outcome of, and impact to, our business and financial operations due to litigation and legal proceedings and tax law changes; our business strategy, including with respect to capital deployment and leverage; our success in identifying, consummating, and integrating, and the impact (financial or otherwise) of, our acquisitions on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, earnings, and synergies, including client overlap; our expectations regarding our expected acquisition and divestiture activity (including timing), including without limitation the effects of the acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS and the completed divestitures of Cell Solutions, CDMO and certain of our Discovery business assets; our strategic agreements with our clients and opportunities for future similar arrangements; the timing of and our ability to obtain new clients in targeted market segments and/or to predict which client segments will be future growth drivers; the impact of our investments in specified business lines, products, sites and geographies; our expectations on the impact of artificial intelligence in biopharma research & development, including regulatory approvals; our ability to meet economic challenges; and Charles River’s future performance as otherwise delineated in our forward-looking guidance. Forward-looking statements are based on Charles River’s current expectations and beliefs, speak only as of the date of this presentation, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward- looking statements. Those risks and uncertainties include, but are not limited to: the impact of the events described herein, changes and uncertainties in the global economy and financial markets, including any changes in business, political, or economic conditions; the ability to successfully integrate businesses we acquire and additional risks and uncertainties that accompany such businesses (including K.F. (Cambodia) Ltd. and PathoQuest); the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry and market trends and conditions; new displacement technologies; U.S. Department of Agriculture (“USDA”) and Food and Drug Administration (“FDA”) regulations; changes in law; continued availability of products and supplies; the impact of unauthorized access into our information systems; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River’s Annual Report on Form 10-K as filed on February 18, 2026, as well as other filings we make with the Securities and Exchange Commission. Because forward- looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River. Charles River assumes no obligation and expressly disclaims any duty to update information contained in this presentation except as required by law. Regulation G This presentation includes discussion of non-GAAP financial measures. We believe that the inclusion of these non-GAAP financial measures provides useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often one-time charges, consistent with the manner in which management measures and forecasts the Company’s performance. The non-GAAP financial measures included in this presentation are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. In accordance with Regulation G, you can find the comparable GAAP measures and reconciliations to those GAAP measures on our website at ir.criver.com.